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Abstract
Introduction Health-related quality of life (HRQOL) is a
legitimate construct for evaluating treatment and its side
effects. Recently, predictive value of HRQOL on survival
also has been of interest. In light of the longer survival in
patients with prostate cancer and importance of quality of
life, we seek to evaluate the association between HRQOL
and survival using traditional and novel techniques.
Methods Patients from CaPSURE (Cancer of the Prostate
Strategic Urologic Research Endeavor) who were treated
within 6 months of diagnosis and had pre-treatment and
sufficient post-treatment follow-up information constituted
the study population. A sample consisting of 2,899 patients
met the study criteria. SF-36 domains were used to measure
HRQOL outcomes. Categorical variables were created for
HRQOL based on the baseline distribution of the lower
10th percentile and the remainder of the patients. Associ-
ation between HRQOL and survival (defined by all-cause
mortality) in patients with prostate cancer was evaluated
using Cox proportional hazards models controlling for age
at diagnosis, type of treatment received, clinical risk clas-
sification, and number of comorbidities. Sequential boot-
strap resampling was implemented to evaluate stability of
the model. Univariate and multivariate Cox proportional
hazards models were fit using various time points over the
course of follow-up.
Results In the analysis looking at association of HRQOL
baseline measurements, higher levels of physical func-
tion and general health were significantly associated with
better survival (HR 0.49 95% CI 0.32–0.78 and HR 0.51
95% CI 0.35–0.75, respectively). Post-treatment analysis
demonstrated similar results. In time-dependent analysis,
higher levels of physical function, role physical, and gen-
eral health were significantly associated with better sur-
vival (HR ranged from 0.57 to 0.65). In addition, analysis
looking at change in HRQOL scores demonstrated an
association between higher scores on physical function,
role physical, vitality, social function, and general health
and longer survival (HR ranged from 0.56 to 0.63).
Conclusion This study demonstrated that several domains
of HRQOL were significantly associated with survival in a
large group of patients with localized prostate cancer. This
association was maintained over the course of disease
regardless of the time of the assessment. Results from our
study have both research and clinical relevance. They
could provide information that enable us to not only
improve communication with patients and families, but
also to develop interventions and treatments best suited for
the patient.
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Introduction
The burden that disease places on patients, families, and
society has become an important consideration in health
care [1]. With more people living with chronic conditions,
cancer included, quality of life, in addition to the tradi-
tional outcomes such as morbidity and mortality, becomes
an important factor in decision-making interventions and
program development [2].
With improvements in diagnosis and treatment, there
has been a marked increase in long-term cancer survivors
in the past decade [3]. Although numerous studies exist on
both general and disease-related quality of life in cancer
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survivors, most of the research covers periods close to
diagnosis and treatment. A variety of factors such as a
patient’s clinical and sociodemographic characteristics,
level of function prior to treatment, and type and side
effects of treatment could influence survival over the
course of disease. Moreover, predictive value of quality of
life measured at various points over the course of disease
could provide information on complex pathways between
physical and psychological manifestations of disease.
Recently, numerous studies addressed the question of
predictive value of HRQOL in survival [4–12]. It has been
shown that HRQOL can independently predict survival in
several types of diseases, independent of clinical and
demographic characteristics of the patient. In a majority of
studies, HRQOL measures assessed at baseline (i.e. before
treatment started) demonstrated a strong association with
survival for a variety of conditions, ranging from advanced
lung carcinoma, breast carcinoma, multiple myeloma,
melanoma, esophageal carcinoma, head and neck carci-
noma, and advanced prostate cancer, while some of the
studies report no association [4–11, 13].
In the last decade, there has been an upsurge of HRQOL
research in the field of prostate cancer. Controversy sur-
rounding screening, diagnosis, and treatment of prostate
cancer indicates the particular importance of quality of life
measurements. Evaluations of HRQOL outcomes in pros-
tate cancer treatments have focused on the specific areas of
functioning rather than broader physical, emotional, and
social well-being. Studies evaluating specific outcomes
after treatment concluded that sexual function declines
rapidly after radical prostatectomy with eventual improve-
ment, while external beam radiation produce smaller but
more prolonged impairments [14, 15]. However, there have
been a limited number of the studies evaluating predictive
value of HRQOL and survival in prostate cancer patients,
with the majority of them examining patients with meta-
static prostate cancer. In the study by Collette et al., baseline
HRQOL scores were associated with survival in 391
patients with metastatic disease. However, the investigators
concluded that the addition of HRQOL variables did not
improve the predictive power of clinical and biochemical
factors on survival models [5]. Sullivan and colleagues
described the relationship between HRQOL measurements
at baseline, 4, and 12 weeks in 809 patients and determined
that both baseline and change scores were significantly
associated with a variety of outcomes [11].
As life expectancy increases in patients with clinically
localized prostate cancer, evaluation of the long-term
effects of treatment on survival becomes more imperative.
At the same time, the absence of sufficient clinical and
treatment-related quality of life follow-up in large popula-
tions of patients with localized disease is a major obstacle in
assessing changes of QOL over time. Numerous clinical and
psychological factors, such as diagnosis, treatment, recov-
ery, and side effects could influence a patient’s own health
perception and affect his general health over time. Longi-
tudinal studies of prostate cancer have shown that a
patient’s QOL scores are likely to change over the course of
follow-up, and failure to examine trends across numerous
consecutive time points could lead to underestimation of
true associations between HRQOL and clinical outcomes
[16–18]. Several studies have addressed the dynamic rela-
tionship between serial measurements of HRQOL and
survival, demonstrating that results over time differ from
cross-sectional assessments. In the study by Ferraro and
Kelley-Moore, the association between self-reported health
(SHR) and mortality was demonstrated only when SHR
measurements were treated as time-dependent covariates
[17]. At the same time, in the analysis by Lyyra et al., use of
time-dependent Cox proportional hazards models enabled
investigators to demonstrate increased association of SHR
and mortality in both men and women [16]. Given longer
survival of patients with prostate cancer and greater
emphasis on improving quality over quantity of life, it is
important to incorporate the time-dependent nature of
HRQOL into prostate cancer research.
Although studies reporting predictive effects of HRQOL
on survival have been plentiful, there are several factors
that could make interpretation of results difficult. Insuffi-
cient adjustment for known clinical prognostic factors and
ignoring correlations between scales used to measure
HRQOL are just two of them. A recent paper by Van Steen
et al. discussed these issues [19]. In addition, methods to
address those issues in the context of Cox Regression
models have been developed by Sauerbrei and Schumacher
[20].
In the current study, traditional analysis of the associa-
tion between HRQOL and survival is enhanced by boot-
strap resampling techniques that are used in effort to avoid
possible biases in selection of variables for each model,
and implementation of the time-dependent survival analy-
sis to account for the dynamic nature of HRQOL.
The goal of the present study was to assess whether
HRQOL (as both a constant and a time-dependent covari-
ate) measured (1) at baseline, (2) at post-treatment, and (3)
as change between baseline and the time preceding out-
comes (death) is associated with survival.
Materials and methods
Study population
CaPSURETM (Cancer of the Prostate Strategic Urologic
Research Endeavor) patients are recruited from 40 com-
munity-based, academic, and veterans affairs (VA) urology
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practices across the United States by participating urolo-
gists who report clinical data and follow-up information
on diagnostic tests and treatments. Approximately 80% of
patients are drawn from community-based practices in 25
states, ensuring a broad representation of geographically
diverse community patients. HRQOL data are obtained
from a self-administered questionnaire sent to each
patient’s home biannually. Patients are treated according to
their physicians’ usual practices and are followed until time
of death or withdrawal from the study. Detailed descrip-
tions of the CaPSURE study populations and methods have
been published previously [21, 22].
Men who were newly diagnosed at entry to CaPSURE
had information on initial treatment and had serial (base-
line, immediate post-treatment, and at least one longer
post-treatment) quality of life assessments made up the
study population. As of June 2007, 13,124 patients were
enrolled in CaPSURE. Of these, 8,667 were newly diag-
nosed (i.e. enrolled within 6 months of diagnosis) and had
information on initial treatment; and 2,899 had HRQOL
assessments prior to treatment as well as within 2 years
after treatment.
Outcomes measured
General health-related quality of life (HRQOL) was mea-
sured using RAND 36-item (SF-36), version 1.0 health
survey. This instrument includes eight individual domains,
four physical and four mental: physical functioning (PF),
role limitation because of physical problems (RP), bodily
pain (BP), general health perception (GH), role limitations
because of emotional problems (RE), energy/fatigue (VT),
emotional well-being (MH), and social functioning (SO)
and two summary scores, measuring physical and mental
components [23]. Results of each score are standardized to
go from 0 to 100, with higher scores representing better
outcomes. For ease of interpretation, categorical variables
were created for HRQOL based on the baseline distribution
of the lower 10th percentile and the remainder of the
patients. In addition, continuous values of HRQOL out-
comes were tested.
All-cause and disease-specific mortality were reported
by treating physicians or next of kin and confirmed by
death certificates or national death index (NDI) when the
death certificates were unavailable.
Type of treatment was defined as radical prostatectomy
(RP)-surgical removal of prostate, external beam radiation
(XRT), cryotherapy (Cryo), and hormonal treatment (HT).
Watchful waiting patients were not included in study
population due to small sample size and insufficient
follow-up data.
Demographic and clinical characteristics of the study
population such as race/ethnicity, BMI, and marital status
were evaluated in initial analysis. They were not included
in the main analysis due to poor distribution of values in
the study population or irrelevance to the research question.
Age at diagnosis was included as both continuous and a
categorical variable with four levels: \55 years old, 55–
64 years old, 65–74 years old, and[75 years old. Number
of comorbidities at baseline was defined as a categorical
variable with three levels: no comorbidities, one to three,
and greater than three. Pre-treatment clinical stage, Glea-
son grade, and prostate-specific antigen (PSA) level were
combined into prostate cancer risk categories, as described
by D’Amico et al. [24]: low risk (stage T1 or 2a, Gleason
score 2–6, PSA level\10 ng/mL), intermediate risk (stage
T2b or Gleason score 7 or PSA between 10 and 20 ng/mL),
and high risk (any stage greater than T2b, Gleason score
8–10, PSA level [20 ng/mL). In addition, separate com-
ponents of risk classification categories.
Statistical methods
Association between HRQOL and survival in patients with
prostate cancer was evaluated using Cox proportional
hazards models to estimate hazard ratios (HR) that presents
a relative risk of survival between groups with different
values of baseline HRQOL.
Sequential bootstrap resampling was implemented to
identify the most stable variables associated with survival.
This process was modeled on the research by Messinger-
Rapport et al. [25] and methods developed by Sauerbrei
and Schumacher [20]. This method incorporates stepwise
selection with data-dependent methods of choosing vari-
ables. It gives an ability to evaluate both the distribution
and contribution of each variable to the stability of a
model, and could help in evaluation of the different stages
of significance. Bootstrap resampling involved creating
new random datasets from the original dataset with each
dataset then undergoing Cox analysis with stepwise
selection. The process was repeated 1,000 times, and the
percentage of each variable included in the analysis was
calculated. Those variables that entered the models at least
50% of the times are used for the final Cox analysis to
estimate HR and 95% confidence intervals (CI).
Initially, univariate Cox proportional hazards model
were fit for each baseline HRQOL outcome to determine
which were related to overall survival.
Then, a series of multivariate models that included all
HRQOL domains, type of initial treatment, prostate cancer
disease severity, age at diagnosis, and number of comor-
bidities (chosen a priori for initial analysis) were used to
determine the effect of HRQOL on survival at various time
points over the course of disease. It should be noted that
inferences from estimates in our models could be biased
since they are based on the assumptions that the model is
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defined by choice of ‘correct’ variables; thus, this inference
should be considered informal.
First, the associations of the baseline measurements (i.e.
measurements reported prior to treatment) and overall
survival were evaluated. Second, measurements reported in
the first year after treatments were evaluated in a similar
model. Third, to account for changes in HRQOL over time,
a Cox proportional hazards regression model with time-
dependent covariates was run [26]. This method allowed
the calculation of hazards at specific times that depended
on the values of other covariates in the model [27]. Fourth,
to account for changes in HRQOL, differences between
initial and last HRQOL assessments, defined as either
positive (improvement in HRQOL score) or negative
(decline in HRQOL score) change, were evaluated.
Difference in -2LL statistics were considered to assess
the predictive value of the models with and without
HRQOL for survival.
All analyses were performed using version 9.2 of SAS
for Windows (SAS Institute, Cary, NC).
Results
The study population consisted of 2,899 patients. More
than half of the patients underwent radical prostatectomy as
an initial treatment (58%), with brachytherapy and external
beam radiation constituting another third (22 and 11%,
respectively), and the rest of treatments divided between
cryosurgery and hormonal treatment. Most of the patients
were between 55 and 74 years of age (77%) with the rest
equally divided between a younger and an older group
(\55 and [75). Mean follow-up time from treatment to
either death or last contact was 41.7 months (Q1-24.12,
Q3-56.6). Of the study population, 173 (6%) have died
with 29 (1%) of them dying from prostate cancer. A higher
proportion of deceased was treated with hormonal treat-
ment and external beam radiation (23.75 and 12.35%,
respectively) with the remainder divided between brachy-
therapy and radical prostatectomy. Clinical and sociode-
mographic characteristics of study population are reported
in Table 1. Mean values of baseline and post-treatment
HRQOL are listed in Table 2.
Sequential multivariate Cox regression analysis was
performed using bootstrap resampling to identify the most
stable model. Variables that were entered into the models
more than 50% at the time (500 out of 1,000) were used
for the final models. Subsequent analysis with variables
selected through bootstrapping procedures revealed that
several HRQOL measures are associated with survival
even after adjusting for clinical severity, age, type of
treatment received, and number of comorbidities.
Baseline analysis
In the analysis looking at association of HRQOL mea-
surements at baseline and survival, higher levels of
physical function and general health were significantly
associated with better survival (HR 0.49 95% CI 0.32–0.78
and HR 0.51 95% CI 0.35–0.75, respectively) (Figs. 1, 2).
Post-treatment analysis
Analyses were also conducted to examine the association
between HRQOL measures at 1-year post-treatment and
subsequent survival. Again, physical function and role
physical at 1 year were associated with better survival (HR
0.45 95% CI 0.29–0.67 and HR 0.55 95% CI 0.38–0.79,
respectively) (Figs. 3, 4).
Table 1 Clinical and sociodemographic characteristics of study
population
Study characteristic Value N %
Age at diagnosis \55 314 11
55–64 1,031 36
65–74 1,192 41
75? 362 12
Initial treatment Prostatectomy (RP) 1,682 58
Cryotherapy 128 4
Brachytherapy 605 21
External beam radiation (XRT) 324 11
Hormonal therapy (HT) 160 6
Clinical risk Low 1,253 45
Intermediate 936 34
High 565 21
Deceased No 2,726 94
Yes 173 6
BMI categories Normal (\25.0) 738 26
Overweight (25.0–29.9) 1,481 52
Obese (30–35) 472 17
Very Obese ([35) 141 5
Race/Ethnicity White 2,812 97
Other 87 3
Income \$30,000 673 23
$30,000–50,000 637 22
$50,000–75,000 526 18
[$75,000 800 28
Unknown 263 9
Relationship In relationship 2,623 90
Single 226 8
Unknown 50 2
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Time-dependent covariates
Further analysis was undertaken to account for HRQOL
changes over time by using time-dependent Cox propor-
tional hazards models. In this analysis, HRQOL was
modeled as a variable that may change in value over time.
It was assumed that changes in HRQOL prior to an event
(either death or survival) would be highly associated with
death. In this analysis, treating HRQOL as a time-depen-
dent covariate, higher levels of physical function, role
physical, and general health were significantly associated
with better survival (HR ranged from 0.57 to 0.65).
Change in HRQOL
Analysis was undertaken using either improvement or
decline in HRQOL scores between initial and last HRQOL
assessments. In this analysis, improvement in social func-
tion and general health were associated with higher
survival (HR 0.64 95% CI 0.43–0.94 and HR 0.55 95% CI
0.37–0.82, respectively). A summary of the results of
multivariate analysis are listed in Table 3.
In addition, age (evaluated as both categorical and
continuous measure) and disease severity (evaluated as
D’Amico categories and by inclusion of all components of
Table 2 Mean value of SF-36 scales over time
HRQOL components SF-36 Baseline First year Second year Third year Forth year Fifth year
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Physical function 85.90 (20.17) 81.54 (22.29) 84.36 (21.41) 83.71 (21.95) 83.35 (22.09) 82.88 (22.67)
Role physical 79.65 (35.07) 63.61 (42.64) 76.40 (37.16) 76.84 (37.10) 76.31 (37.15) 75.83 (37.73)
Role emotional 83.65 (31.74) 82.91 (33.16) 86.79 (29.31) 87.01 (29.39) 87.87 (28.37) 88.58 (27.55)
Vitality 67.08 (19.32) 62.57 (20.36) 65.43 (19.95) 65.46 (20.20) 65.82 (20.47) 65.89 (20.47)
Mental health 78.86 (16.03) 80.62 (15.52) 81.31 (15.04) 81.63 (15.12) 81.79 (15.05) 82.28 (14.54)
Social function 88.15 (19.32) 82.50 (23.43) 88.27 (19.47) 88.36 (19.93) 88.48 (20.14) 87.78 (20.87)
Bodily pain 84.28 (19.86) 79.69 (21.86) 82.91 (20.52) 81.89 (20.82) 81.24 (21.04) 80.64 (21.08)
General health 72.43 (19.12) 72.41 (19.39) 72.41 (20.10) 71.97 (20.03) 71.43 (20.64) 71.49 (20.51)
Physical component summary 50.79 (9.20) 47.52 (9.95) 49.59 (9.55) 49.19 (9.83) 48.85 (9.96) 48.65 (10.18)
Mental component summary 52.18 (9.18) 52.67 (8.93) 53.49 (8.24) 53.67 (8.43) 53.97 (8.54) 54.25 (8.01)
Fig. 1 Overall mortality by general health level at baseline
Fig. 2 Overall mortality by physical function at baseline
Fig. 3 Overall mortality by general health level post-treatment
Fig. 4 Overall mortality by physical function post-treatment
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the risk categories) were associated with survival (see
Table 3). Type of treatment was associated with survival as
well, with patients who underwent radical prostatectomy
having higher survival compared to other types of treat-
ment (results are not reported and available upon request).
The difference in -2LL statistics was 476 for the model
Table 3 Results from multivariate Cox regression model (a) baseline, (b) time-dependent analysis, and (c) decline in HRQOL between baseline
and last assessment
Parameter Hazard ratio 95% confidence limits
(a)
Physical function Lower 10% percentile Referent
Remainder 90% 0.51 (0.277–0.936)
General health Lower 10% percentile Referent
Remainder 90% 0.35 (0.194–0.628)
Age \55 Referent
55–64 1.88 (0.72–4.86)
65–74 2.84 (1.12–7.22)
75? 2.91 (1.08–7.02)
Clinical risk Low Referent
Intermediate 1.29 (0.615–2.703)
High 2.78 (1.408–5.471)
Parameter Hazard ratio 95% confidence limits
(b)
Physical function Lower 10% percentile Referent
Remainder 90% 0.52 (0.34–0.77)
Role physical Lower 10% percentile Referent
Remainder 90% 0.43 (0.29–0.65)
General health Lower 10% percentile Referent
Remainder 90% 0.35 (0.24–0.52)
Age \55 Referent
55–64 2.43 (0.85–6.92)
65–74 3.76 (1.37–10.32)
75? 4.90 (1.74–13.78)
Clinical risk Low Referent
Intermediate 1.35 (0.88–2.07)
High 2.02 (1.32–3.10)
Variables Value Hazard ratio 95% confidence limits
(c)
Social function Decline Referent
Improvement 0.64 (0.43–0.94)
General function Decline Referent
Improvement 0.55 (0.37–0.82)
Risk categories
Low Referent
Medium 1.62 (1.09–2.40)
High 2.51 (1.67–3.76)
Age
[55 Referent
55–64 1.60 (0.61–4.18)
65–75 3.69 (1.47–9.2)
[75 6.75 (2.65–17.92)
1024 Qual Life Res (2009) 18:1019–1027
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including HRQOL and 190 for the model without HRQOL
Thus, 39.9% of the predictive information of the full
multivariable model was contributed by HRQOL measures.
Discussion
In the study of the 2,899 men with localized prostate cancer,
we examined both fixed (baseline and post-treatment) and
time-varying association between HRQOL and survival. In
the current study, patients reporting higher scores on several
domains in SF-36 scales demonstrated lower likelihood of
dying. In addition, those domains displayed a stable asso-
ciation with survival regardless of the period in treatment
process, thus implying an important role of HRQOL in the
survival in the patients with prostate cancer.
The associations found in our study are consistent with
findings by other investigators; however, to our knowledge,
it is the first study that investigated the relationship
between HRQOL and survival in localized prostate cancer.
In addition, results from our study demonstrated consis-
tent association between HRQOL over time, underscoring
importance of those outcomes in the course of disease and
survivorship.
In the univariate analysis, higher scores on the majority
of HRQOL domains were associated with better survival.
Following the use of a sequential bootstrap technique, only
physical function and general health demonstrated a strong
association with survival. Two studies looking at associa-
tion of HRQOL and survival in the patients with metastatic
hormone-refractory prostate cancer showed similar results.
In the study by Sullivan et al., hazard of death for patients
whose baseline FACT-P grand total score was greater than
median was 73% of the hazard for the patients whose
baseline scores was less or equal to median [11]. In the
study by Collette et al., only items of appetite loss and
insomnia were retained as independent predictors [5].
Nevertheless, Collette and colleagues concluded that
HRQOL measurements did not add to the predictive ability
of the models. Similar results were reported in breast
cancer populations [8, 13, 28] although findings from the
studies in non-metastatic cancer did not provide evidence
of an association between baseline HRQOL and survival
[6, 28].
Studies that evaluated the relationship between post-
treatment assessments of HRQOL and survival reported
mixed results. In the study by Coates et al., post-relapse
scores were highly associated with survival, but were more
pronounced in advanced disease [28]. In the study by
Sullivan and colleagues, 12 week change scores were sig-
nificant predictors of survival. Our results are consistent
with these findings, demonstrating that change between
baseline and the last assessment before the event in
physical function, role physical, vitality, social function,
and general health were highly associated with survival.
Addition of the time-dependent covariates to the con-
ventional Cox proportional hazards models is thought to
better reflect the dynamic nature of the disease. In the study
by Lyyra et al., the addition of the time-dependent covari-
ates led to the discovery of an association between self-
reported health and survival while conventional analysis did
not reveal those associations [16]. The study by Kalantar-
Zadeh and colleagues concluded that even though results
from cross-sectional and time-dependent analysis of the
association of osteodystrophy indicators in hemodialysis
patients and survival were similar, subtle but potentially
clinically relevant differences existed [29]. In our study,
domains that were not initially identified in the conven-
tional analysis were detected as an independently associated
with survival. Relative risk for all-cause mortality was
significantly lower for the patients reporting higher scores
for role physical, physical function, and general health.
The mechanisms of the relationship between self-
reported HRQOL and survival are not very well under-
stood. Further investigation of these relationships could
provide evidence of the pathways between physical and
psychological manifestation of disease and might reflect
patients’ perceptions of the severity of underlying disease.
A causal relationship between better HRQOL and survival
has been suggested, although evidence is limited. One
explanation of the predictive value of HRQOL is driven by
the theory that patients are aware of the severity of the
disease beyond the realm of conventional techniques (such
as clinical characteristics), and this perception affects
HRQOL self-reporting [28]. Moreover, it could be specu-
lated that some domains of HRQOL might be a surrogate
for possible symptoms and events, or HRQOL may be a
marker for otherwise undetected prognostic factor.
Identification of prognostic factors for survival serves an
important purpose. It could lead to modification of treatment
regimens from aggressive to more palliative, as well as help
identify subsets of patients for whom interventions could be
applied. Because HRQOL is a multidimensional measure, it
provides a more complete picture of patient’s well-being
beyond clinical characteristics. In addition, measures
obtained during treatment might indicate a combined effect
of the tumor response and an acute complication, and could
be used as a supplemental parameter to modify the strategy
for treatment. It should be noted that the importance of
predictive value of HRQOL ought to be treated with caution.
It has been shown that improvements in psychological sup-
port led to improvement in survival in breast cancer patients,
as well as improvements in weight control [30]. However,
until we can demonstrate that improvements in HRQOL
could lead to improvement in survival after prostate cancer
treatment, our findings are not necessarily causal.
Qual Life Res (2009) 18:1019–1027 1025
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Several limitations exist in our study. Studies looking at
the prognostic value of HRQOL used different instruments,
making comparisons difficult. However, the majority of
them demonstrated results in similar domains. In addition,
it has been reported in several studies that comparability
between different instruments is satisfactory. The risk of
biases associated with use of an observational database that
utilized non-random samples of the men are anticipated.
Because our study concentrated on evaluation of the
HRQOL over different time points, not all patients in the
database have sufficient data, thus were not included in
the analysis. Evaluation of the comorbidities was utilized
by simple enumeration, which is a less than ideal measure
of concurrent disease. However, we plan on utilizing
expanded measures (TIBI-CaP) in future studies [31].
While race is considered to be an important factor that
could influence survival, it was not evaluated based on the
fact that more than 90% of the study population was white/
non-Hispanic, and inclusion of this variable would have
reduce the power of the analysis.
While recognizing those limitations, our study has many
advantages as well. Men in the CaPSURETM database
attend a geographically diverse group of mostly commu-
nity-based practices and in general reflect treatment trends
in the field. Longer follow-up and availability of baseline
information on QOL allowed us to observe the effects of
diagnosis, treatment, and survival over the natural course
of disease. Several steps were taken to address effects
of multicollinearity and the time-dependent nature of
HRQOL. To our knowledge, it is the first study that eval-
uates association of HRQOL and survival in a large group
of men with localized prostate cancer.
In conclusion, this study found that several domains of
HRQOL were significantly associated with survival in a
large group of patients with localized prostate cancer.
These associations were maintained over the course of the
disease regardless of the time of the assessment. Results
from our study have both research and clinical relevance.
They could provide us with information that would enable
us to not only improve communication with patients and
families, but to provide interventions and treatment best
suitable for the patient.
Open Access This article is distributed under the terms of the
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